-

Cleerly AI-QCT Demonstrates High Agreement with Invasive IVUS in INVICTUS Registry

Multicenter INVICTUS Registry Demonstrates Strong Correlation Between Noninvasive AI-QCT and Invasive IVUS for Coronary Plaque Quantification

DENVER--(BUSINESS WIRE)--Cleerly, a leader in AI-based cardiovascular imaging analysis, presented findings from its multicenter INVICTUS registry at the recent European Congress of Radiology (ECR 2026) in Vienna, Austria. The presentation titled, “Artificial Intelligence-Based CCTA Quantification of Atherosclerosis Burden: Comparison With IVUS in the INVICTUS Registry” was presented by Rine Nakanishi, MD, PhD, during the Clinical Trials in Radiology: Spotlight Session on March 5, 2026. The analysis has also been simultaneously published in European Radiology.

"The strong correlations across multiple metrics support AI-QCT as a reliable tool for comprehensive coronary plaque assessment,” said James K. Min, founder and CEO of Cleerly.

Share

INVICTUS, a multicenter registry of two cohorts of patients prospectively and retrospectively enrolled across 17 centers in Japan, aimed to evaluate the quantification and characterization of atherosclerosis by artificial intelligence-enabled quantitative computed tomography (AI-QCT) against “gold-standard” invasive imaging techniques such as intravascular ultrasound (IVUS), near-infrared spectroscopy IVUS (NIRS-IVUS), and optical coherence tomography (OCT).

IVUS is widely used during invasive coronary procedures to assess plaque burden and guide intervention. The authors investigated the diagnostic utility of AI-QCT quantification of coronary atherosclerosis across the whole spectrum of atheroma burden, including diseased and non-diseased continuous vascular segments.

Key Findings

AI-QCT demonstrated strong correlations compared to invasive "gold-standard" imaging IVUS, showing no significant difference in measuring arterial plaque across the whole coronary segment. AI-QCT showed strong correlation with IVUS (mean difference −0.09%), with 94.4% of measurements falling within the limits of agreement. Strong associations were seen between AI-QCT and IVUS in quantifying external elastic membrane volume (EEM) (r=0.899), lumen volume (r=0.943), plaque volume (r=0.833), length-normalized PAV (r=0.851), and calcium index (r=0.960). AI-QCT also demonstrated 99.1% agreement in classifying the predominant plaque type at the minimum lumen area. Strong correlations were also seen in segments with non-calcified plaque (NCP) and low-attenuation (LAP) for vessel, lumen, and plaque volumes.

Clinical and Strategic Implications

Unlike physiology-based imaging approaches that focus primarily on ischemia assessment, AI-QCT provides a comprehensive analysis of both total plaque burden and plaque composition using standard coronary computed tomography angiography (CCTA). These findings support the use of noninvasive plaque quantification with standard CCTA for comprehensive coronary plaque assessment.

"Every time we reach a scientific milestone that makes accurate plaque characterization more accessible and less invasive, we get closer to our goal of eliminating heart attacks. IVUS has long been the gold standard in invasive plaque imaging, and the findings from INVICTUS represent an important advance in establishing the clinical validity of noninvasive plaque quantification. The strong correlations across multiple metrics support AI-QCT as a reliable tool for comprehensive coronary plaque assessment,” said James K. Min, founder and CEO of Cleerly.

Visit www.cleerlyhealth.com to learn more.

About Cleerly

Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.

Contacts

Cleerly Media Contact
Christy Sievert
press@cleerlyhealth.com

More News From Cleerly

PARAMOUNT, the First Randomized Trial of AI-Enabled Plaque-Based Care, Meets Primary Endpoint in Late-Breaking Results at AHA 2026

DENVER--(BUSINESS WIRE)--Cleerly, a leader in advanced cardiovascular imaging analysis, today presented primary results from PARAMOUNT, the first randomized trial of AI-QCT-guided care against usual care, as Late-Breaking Science at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowe...

Cleerly to Present Late-Breaking Results from the First Randomized Trial of AI-QCT-Guided Care in Patients with Stable Chest Pain at AHA 2026

DENVER--(BUSINESS WIRE)--Cleerly, a leader in AI-based cardiovascular imaging, announces its participation in the American Heart Association (AHA) Scientific Sessions 2026, November 6 to 9 at McCormick Place Convention Center in Chicago, Illinois. Cleerly will share primary results from PARAMOUNT, the first randomized trial to compare personalized care guided by AI-based quantitative coronary CT analysis (AI-QCT) with usual care in symptomatic patients with suspected coronary artery disease (CA...

Cleerly's TRANSFORM Trial Sends a Mobile CT Scanner Across the South to Reach Patients in Underserved Communities

DENVER--(BUSINESS WIRE)--Cleerly, a leader in advanced cardiovascular imaging analysis, and Clear Heart and Lung Imaging, a leader in outpatient imaging care, have taken a cardiac-capable mobile CT scanner across the southern United States to expand access to cardiovascular research and enable communities and clinics to participate in Cleerly's TRANSFORM Trial. From July through September 2026, the CT scanner traveled through Arizona, Louisiana, Georgia, and Florida, bringing cardiovascular ima...
Back to Newsroom